Improving the justice-based argument for conducting human gene editing research to cure sickle cell disease
In a recent article, Marilyn Baffoe-Bonnie offers three arguments that conducting CRISPR/Cas9 biotechnology research to cure sickle cell disease (SCD) would help address historical and current injustices in SCD research and care. I will grant that the first argument is sound, but show that the secon...
| Главный автор: | |
|---|---|
| Другие авторы: | |
| Формат: | Электронный ресурс Статья |
| Язык: | Английский |
| Проверить наличие: | HBZ Gateway |
| Journals Online & Print: | Загрузка...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Опубликовано: |
Wiley-Blackwell
[2020]
|
| В: |
Bioethics
Год: 2020, Том: 34, Выпуск: 2, Страницы: 200-202 |
| Индексация IxTheo: | NCH Медицинская этика NCJ Научная этика |
| Другие ключевые слова: | B
CRISPR
B Biotechnology B Distributive Justice B Gene Therapy B Sickle cell disease B benefit-sharing |
| Online-ссылка: |
Presumably Free Access Volltext (Verlag) Volltext (doi) |
| Итог: | In a recent article, Marilyn Baffoe-Bonnie offers three arguments that conducting CRISPR/Cas9 biotechnology research to cure sickle cell disease (SCD) would help address historical and current injustices in SCD research and care. I will grant that the first argument is sound, but show that the second and third arguments suffer from roughly the same defect, which is that they really argue for something else rather than for conducting CRISPR/Cas9 research to cure SCD. I conclude that a better justice-based argument would use only Baffoe-Bonnie’s first argument. |
|---|---|
| ISSN: | 1467-8519 |
| Reference: | Kritik von "A justice-based argument for including sickle cell disease in CRISPR/Cas9 clinical research (2019)"
|
| Второстепенные работы: | Enthalten in: Bioethics
|
| Persistent identifiers: | DOI: 10.1111/bioe.12690 |